Annals of Internal Medicine, ISSN 0003-4819, 01/2012, Volume 156, Issue 1, pp. 1 - 10
Background: Mechanical neck pain is a common condition that affects an estimated 70% of persons at some point in their lives. Little research exists to guide...
MEDICINE, GENERAL & INTERNAL | CHIROPRACTIC CARE | LOW-BACK-PAIN | CLINICAL-TRIAL | WHIPLASH-ASSOCIATED DISORDERS | GENERAL-PRACTITIONER | PHYSICAL-THERAPY | COVARIATE ADJUSTMENT | DISABILITY INDEX | MANUAL THERAPY | 2000-2010 TASK-FORCE | Acetaminophen - adverse effects | Acute Disease | Neck Pain - therapy | Humans | Middle Aged | Male | Treatment Outcome | Analgesics, Non-Narcotic - therapeutic use | Young Adult | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Time Factors | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Analgesics, Non-Narcotic - adverse effects | Adolescent | Manipulation, Spinal - adverse effects | Adult | Female | Aged | Neck Pain - drug therapy | Acetaminophen - therapeutic use | Pain Measurement | Exercise Therapy - adverse effects | Neck pain | Care and treatment | Exercise | Spinal adjustment | Physiological aspects | Research | Health aspects
MEDICINE, GENERAL & INTERNAL | CHIROPRACTIC CARE | LOW-BACK-PAIN | CLINICAL-TRIAL | WHIPLASH-ASSOCIATED DISORDERS | GENERAL-PRACTITIONER | PHYSICAL-THERAPY | COVARIATE ADJUSTMENT | DISABILITY INDEX | MANUAL THERAPY | 2000-2010 TASK-FORCE | Acetaminophen - adverse effects | Acute Disease | Neck Pain - therapy | Humans | Middle Aged | Male | Treatment Outcome | Analgesics, Non-Narcotic - therapeutic use | Young Adult | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Time Factors | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Analgesics, Non-Narcotic - adverse effects | Adolescent | Manipulation, Spinal - adverse effects | Adult | Female | Aged | Neck Pain - drug therapy | Acetaminophen - therapeutic use | Pain Measurement | Exercise Therapy - adverse effects | Neck pain | Care and treatment | Exercise | Spinal adjustment | Physiological aspects | Research | Health aspects
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9739, pp. 419 - 430
Summary Background Hyperglycaemia is associated with increased risk of cardiovascular complications in people with type 2 diabetes. We investigated whether...
Internal Medicine | URINARY ALBUMIN EXCRETION | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | RETINOPATHY | COMPLICATIONS | MELLITUS | PROGRESSION | Glycated Hemoglobin A - analysis | Blood Glucose - analysis | Diabetic Neuropathies - prevention & control | Humans | Middle Aged | Diabetes Mellitus, Type 2 - blood | Diabetic Retinopathy - prevention & control | Hypoglycemic Agents - administration & dosage | Lipids - blood | Adult | Aged | Diabetic Angiopathies - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Diabetic Nephropathies - prevention & control | Type 2 diabetes | Complications and side effects | Care and treatment | Hyperglycemia | Patient outcomes | Cardiovascular diseases | Risk factors | Clinical trials | Cardiovascular disease | Diabetes | Eye
Internal Medicine | URINARY ALBUMIN EXCRETION | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | RETINOPATHY | COMPLICATIONS | MELLITUS | PROGRESSION | Glycated Hemoglobin A - analysis | Blood Glucose - analysis | Diabetic Neuropathies - prevention & control | Humans | Middle Aged | Diabetes Mellitus, Type 2 - blood | Diabetic Retinopathy - prevention & control | Hypoglycemic Agents - administration & dosage | Lipids - blood | Adult | Aged | Diabetic Angiopathies - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Diabetic Nephropathies - prevention & control | Type 2 diabetes | Complications and side effects | Care and treatment | Hyperglycemia | Patient outcomes | Cardiovascular diseases | Risk factors | Clinical trials | Cardiovascular disease | Diabetes | Eye
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 9, pp. 818 - 828
In the ACCORD trial, a mean of 3.7 years of intensive glucose lowering increased mortality and reduced nonfatal myocardial infarctions after 5 years of...
MORTALITY | WOMEN | MEDICINE, GENERAL & INTERNAL | GLYCEMIA TREATMENT STRATEGIES | ACCORD TRIAL | FOLLOW-UP | RISK | COHORT | TYPE-2 DIABETES-MELLITUS | Glycated Hemoglobin A - analysis | Cardiovascular Diseases - etiology | Myocardial Infarction - epidemiology | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Treatment Outcome | Diabetes Mellitus, Type 2 - blood | Stroke - etiology | Hypoglycemic Agents - administration & dosage | Cardiovascular Diseases - mortality | Adult | Female | Stroke - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Myocardial Infarction - etiology | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Care and treatment | Blood sugar | Patient outcomes | Cardiovascular diseases | Health aspects | Risk factors | Intervention | Cardiovascular disease | Heart attacks | Diabetes
MORTALITY | WOMEN | MEDICINE, GENERAL & INTERNAL | GLYCEMIA TREATMENT STRATEGIES | ACCORD TRIAL | FOLLOW-UP | RISK | COHORT | TYPE-2 DIABETES-MELLITUS | Glycated Hemoglobin A - analysis | Cardiovascular Diseases - etiology | Myocardial Infarction - epidemiology | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Treatment Outcome | Diabetes Mellitus, Type 2 - blood | Stroke - etiology | Hypoglycemic Agents - administration & dosage | Cardiovascular Diseases - mortality | Adult | Female | Stroke - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Myocardial Infarction - etiology | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Care and treatment | Blood sugar | Patient outcomes | Cardiovascular diseases | Health aspects | Risk factors | Intervention | Cardiovascular disease | Heart attacks | Diabetes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2006, Volume 354, Issue 16, pp. 1685 - 1697
Persons with prehypertension (formerly, “borderline hypertension”) were randomly assigned in a blinded fashion to receive two years of candesartan or placebo,...
UNITED-STATES | SPONTANEOUSLY HYPERTENSIVE RATS | MEDICINE, GENERAL & INTERNAL | NORMAL BLOOD-PRESSURE | METABOLIC CHARACTERISTICS | RISK-FACTORS | CONVERTING-ENZYME-INHIBITOR | CLINICAL-TRIAL | BORDERLINE HYPERTENSION | PREVENTION | PROGRESSION | Antihypertensive Agents - pharmacology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Tetrazoles - pharmacology | Dyslipidemias - complications | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Biphenyl Compounds - therapeutic use | Feasibility Studies | Incidence | Biphenyl Compounds - pharmacology | Hypertension - prevention & control | Adult | Female | Blood Pressure - drug effects | Hypertension - epidemiology | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Obesity - complications | Logistic Models | Obesity - physiopathology | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Benzimidazoles - pharmacology | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Dyslipidemias - physiopathology | Hypertension | Dosage and administration | Research | Drug therapy | Candesartan | Automation | Blood pressure | Lifestyles
UNITED-STATES | SPONTANEOUSLY HYPERTENSIVE RATS | MEDICINE, GENERAL & INTERNAL | NORMAL BLOOD-PRESSURE | METABOLIC CHARACTERISTICS | RISK-FACTORS | CONVERTING-ENZYME-INHIBITOR | CLINICAL-TRIAL | BORDERLINE HYPERTENSION | PREVENTION | PROGRESSION | Antihypertensive Agents - pharmacology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Tetrazoles - pharmacology | Dyslipidemias - complications | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Biphenyl Compounds - therapeutic use | Feasibility Studies | Incidence | Biphenyl Compounds - pharmacology | Hypertension - prevention & control | Adult | Female | Blood Pressure - drug effects | Hypertension - epidemiology | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Obesity - complications | Logistic Models | Obesity - physiopathology | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Benzimidazoles - pharmacology | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Dyslipidemias - physiopathology | Hypertension | Dosage and administration | Research | Drug therapy | Candesartan | Automation | Blood pressure | Lifestyles
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 17, pp. 1575 - 1585
In a randomized trial, 4733 patients with type 2 diabetes mellitus who were at high risk for cardiovascular events received treatment aimed at a target...
PREVENTION | MEDICINE, GENERAL & INTERNAL | HOT | DISEASE | Blood Pressure | Myocardial Infarction - epidemiology | Stroke - prevention & control | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Hypertension - drug therapy | Male | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Glomerular Filtration Rate - drug effects | Hypokalemia - chemically induced | Cardiovascular Diseases - mortality | Creatinine - blood | Hypertension - complications | Female | Stroke - epidemiology | Aged | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Care and treatment | Blood pressure | Cardiovascular diseases | Health aspects | Risk factors | Hypertension | Cardiovascular disease | Diabetes
PREVENTION | MEDICINE, GENERAL & INTERNAL | HOT | DISEASE | Blood Pressure | Myocardial Infarction - epidemiology | Stroke - prevention & control | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Hypertension - drug therapy | Male | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Glomerular Filtration Rate - drug effects | Hypokalemia - chemically induced | Cardiovascular Diseases - mortality | Creatinine - blood | Hypertension - complications | Female | Stroke - epidemiology | Aged | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Care and treatment | Blood pressure | Cardiovascular diseases | Health aspects | Risk factors | Hypertension | Cardiovascular disease | Diabetes
Journal Article